Filing Flows

Filing Flows › Emergent BioSolutions (EBS) › Next earnings date

Emergent BioSolutions (EBS) earnings: beat the estimate

Emergent BioSolutions (EBS) reported on Nov 2, 2026 and beat the EPS estimate: −$0.36 against −$0.39 (+8.0%). Revenue was $110M for Q3 2026, -52% year over year. It beat the EPS estimate in 80% of the quarters on record.

Last result+8.0% vs estimate
Beat rate80%

The last report

Emergent BioSolutions reported revenue of $110M for the third quarter 2026 (-52% Y/Y), net loss $32.7M: MCM Product sales $59.4M, Commercial Product sales $43.5M, All other revenue $7.1M. How it makes money → · Every quarter →

Emergent BioSolutions: EPS against the estimate, last 5 reportsEmergent BioSolutions: EPS against the estimate, last 5 reportsEstimateReported−$0.12$1.06Oct 25$0.11−$0.43Feb 26−$0.25$0.21Apr 26$0.11$0.60Aug 26−$0.39−$0.36Nov 26
Latest (Nov 26): Estimate −$0.39, Reported −$0.36.

Emergent BioSolutions' latest quarter

Emergent BioSolutions, Q3 2026: revenue $110M (-52% year over year), operating margin -33.9%, net loss $32.7M, operating cash flow $100M. The chart follows the revenue to costs, profit and cash.

Questions

Did Emergent BioSolutions beat earnings?

Emergent BioSolutions (EBS) reported on Nov 2, 2026 and beat the EPS estimate: −$0.36 against −$0.39 (+8.0%).

When does EBS report earnings?

The next date is not set yet.

Does Emergent BioSolutions usually beat earnings?

It beat the consensus EPS estimate in 80% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.